
Thymalin is a polypeptide complex extracted from calf thymus glands, developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Soviet Institute of Gerontology — the same research lineage behind Epithalon. It's studied for restoring T-lymphocyte production as the thymus naturally shrinks with age, a process linked to weakening immune function in older adults.
No. It has been used in Russia and former Soviet states since the 1970s but has no FDA or EMA approval and is sold elsewhere for research use only.
A 2003 Khavinson study of 266 elderly patients (thymalin, epithalamin, both, or placebo over 6-8 years) reported a 28% mortality reduction and roughly 4-year median survival advantage in the combined-peptide group. The data is real but Soviet-era, small, geographically narrow, and has not been independently replicated in Western trials — treat it as suggestive, not established.
Both are Khavinson-developed peptide bioregulators from the same research program and were co-administered in his key longevity study, but they target different tissues — Thymalin the thymus/immune system, Epithalon the pineal gland.
Need something specific, or placing a wholesale order? Message us on Telegram — fastest way to reach us.